SON-1010 not checked

Sonnet BioTherapeutics · IL12-FHAB

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SON-1010 is a recombinant, single-chain, unmodified human rIL-12 joined by a flexible linker to the fully human albumin binding (FHAB) domain that "hitch-hikes" on serum albumin for transport to the tumor microenvironment.”In the company’s words, NCT05352750 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Main trialPhase 1
“This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.”In the company’s words, NCT05352750 on ClinicalTrials.gov
Other names
IL12-FHAB

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 30 Jun 2026 Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Phase 1/2Terminated 31 Dec 2025 Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SON-1010

Following is part of Solo: you see every change to SON-1010 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in